Oncodiabetology II. Antidiabetics and cancer prevention / Onkodiabetológia II. Antidiabetikumok és rákmegelozés

The number of patients with type 2 diabetes is increasing worldwide. In Hungary, the prevalence of known diabetic adults exceeds 9.1%, causing increased economical and medical burden to the society. It is obvious that there is a considerable urge to develop novel, safer and more efficient antidiabetic drugs. Therefore, studies have been focusing on the beneficial or detrimental side effects of antidiabetic drugs besides their general metabolic effects. Every anti-diabetic agent has an indirect anti-tumor effect as a consequence of lowering blood glucose levels and controlling carbohydrate, protein and lipid metabolism. In addition, most agents have their own direct antitumor effects, on the other hand, some may play a negligible role in cancer promotion. While the latter possibility is based mainly on pre-clinical, experimental data or on short-duration clinical studies, the informations about the safety of antidiabetic drugs are verified by large-scale, randomized, multicenter, placebo-controlled trials. Nowadays, metformin is the only drug that has been shown to reduce cancer risk in a variety of tumor localizations in monotherapy or in combination with other antidiabetic agents and insulins, and even in combination with certain cytostatics and biological therapies. The available data about the role of other antidiabetics in tumor prevention are less clear or insufficient. Here, we review the available ­ sometimes contradictory ­ literature about the relationship of tumor and antidiabet ics, verifying the safety of antidiabetics. Here, we propose that in the future tumor-specifically optimized antidiabetic treatment may play a role in tumor prevention or even in specific oncotherapy in patients with or without diabetes.

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.

INTRODUCTION: Dry eye disease (DED) is a multifactorial disorder of the ocular surface. The current phase II study was performed to assess the safety and dose regimen of a recently developed topical estradiol formulation for the treatment of DED. METHODS: A total of 104 postmenopausal women suffering from moderate-to-severe DED were included. Topical 17-ß-estradiol-3-phosphate eye drops were administered in three different dosage groups (group 1, 0.05% twice daily; group 2, 0.1% morning, vehicle in the evening; group 3, 0.1% twice daily) and vehicle twice daily as control group for a total period of 3 months. Clinical signs including Schirmer's test and corneal staining were assessed at baseline and at days 14, 30, 60, and 90. Symptoms of DED were measured using the symptom assessment in dry eye (SANDE) test at the same time points. Safety was assessed via frequency of adverse events. RESULTS: Schirmer's test II wetting distance significantly increased in all four groups from baseline to day 90 without significant difference between groups (group 1, + 5.6 ± 6.7 mm/5 min; group 2, + 3.7 ± 4.2 mm/5 min; group 3, + 4.8 ± 4.5 mm/5 min; group 4, + 4.0 ± 5.3 mm/5 min). Statistical significance versus baseline was reached earlier in the treatment groups versus the control group. Corneal staining was significantly reduced after the 3-month treatment period with no significant difference between treatment groups. Staining of the inferior cornea, however, showed a significantly more pronounced decrease in the highest dose group compared to vehicle (p = 0.0463). Symptoms score as assessed with the SANDE test decreased at the end of the treatment period in all four groups. Estradiol eye drops showed a favorable safety profile. CONCLUSION: Our results show that both estradiol eye drops and vehicle are safe and reduce signs and symptoms in postmenopausal women with moderate-to-severe DED. Although the study failed to reach the primary outcome to demonstrate a significant difference between the estradiol eye drops and vehicle in Schirmer's test, improvement occurred earlier in the active groups compared to the control group. The data of the current study will serve as a basis for a larger phase III study to establish a potential therapeutic effect of topical estradiol eye drops. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov registry NCT03821415.

[Clear cell adenocarcinoma of the tongue. Coincidence or distant metastasis?]. / Világossejtes adenocarcinoma a nyelvben. Koincidencia vagy attét?

Malignant tumors of the salivary glands are rare, they account for less than 0.5% of all malignancies and for 5% of cancers of maxillofacial regions. Clear cell adenocarcinoma represents 1% of malignant tumors of the salivary glands. The present case involved a 63-years-old Hungarian woman with a painless, non-ulcerated, nodular mass on the right side of the middle part of the tongue. Her past medical history included right nephrectomy of renal cell carcinoma, seven years before the tongue tumor. The initial orofacial clinical examination suspected lipoma, neurinoma or distant metastasis of the renal cell carcinoma. The histomorphological analysis of the resected tongue tumor showed similar clear cell adenocarcinoma mimicking the phenotype of renal cell carcinoma but detailed immunohistochemical analysis proved the primary origin of tongue indicating second primary metachronous malignant tumor.

[Evaluation of colonic anastomoses performed in the last twenty-five years]. / 25 év alatt végzett elektív vastagbél-anastomosisok értékelése.

AIMS: The authors scrutinize the results of elective large-bowel operations, comparing the healing of handsewn and stapled anastomoses. A brief history of large-bowel surgery is also presented. METHODS: Altogether 710 elective colonic anastomoses were made between 01. January 1979. and 31. December 2004. are evaluated. The complications and mortality rate after these operations are also mentioned. The 710 large-bowel anastomoses were performed under standard personal and material conditions 2/3 of them handsewn, while 1/3 by the stapled method. RESULTS: According to the operation results no significant differences in morbidity and mortality were found between the two technics. CONCLUSION: Stapled anastomoses are more expensive, but in case of recto-sigmoid tumours, particularly in low rectum resections, the instruments are indispensable.